A Retrospective, Multi-centre, Non-interventional Study Investigating the Clinical Parameters Associated With Saxenda® Use and Discontinuation in Patients in Turkey. INSPIRE Turkey (INvestigate the Impact of Saxenda® on Patient's Weight In a REal World Setting in Turkey) Study
Latest Information Update: 27 Jan 2023
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms INSPIRE Turkey
- Sponsors Novo Nordisk
Most Recent Events
- 23 Jan 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 05 Dec 2022 Planned End Date changed from 30 Sep 2022 to 30 Dec 2022.
- 05 Dec 2022 Planned primary completion date changed from 30 Sep 2022 to 30 Dec 2022.